

# Robert M Prins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5402509/publications.pdf>

Version: 2024-02-01

90  
papers

11,354  
citations

76326

40  
h-index

60623

81  
g-index

94  
all docs

94  
docs citations

94  
times ranked

15300  
citing authors

#	ARTICLE	IF	CITATIONS
1	Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors. <i>NMR in Biomedicine</i> , 2023, 36, .	2.8	7
2	Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. <i>Neuro-Oncology</i> , 2022, 24, 1020-1028.	1.2	12
3	The current landscape of immunotherapy for pediatric brain tumors. <i>Nature Cancer</i> , 2022, 3, 11-24.	13.2	21
4	The future of cancer immunotherapy for brain tumors: a collaborative workshop. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	7
5	The immune landscape of common CNS malignancies: implications for immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 729-744.	27.6	50
6	Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. <i>Nature Communications</i> , 2021, 12, 4031.	12.8	21
7	Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021, 23, 356-375.	1.2	59
8	Is there a role for neoadjuvant anti-PD-1 therapies in glioma?. <i>Current Opinion in Neurology</i> , 2021, Publish Ahead of Print, 834-839.	3.6	0
9	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. <i>Nature Cancer</i> , 2021, 2, 1372-1386.	13.2	39
10	Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. <i>Nature Communications</i> , 2021, 12, 6938.	12.8	93
11	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 5232-5245.	7.0	52
12	Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. <i>Neuro-Oncology</i> , 2020, 22, 1425-1438.	1.2	37
13	IMMU-30. UPREGULATED T CELL AND INTERFERON- $\gamma$ -RELATED GENE EXPRESSION IS ASSOCIATED WITH INCREASED SURVIVAL IN RECURRENT PEDIATRIC HIGH-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, iii365-iii366.	1.2	0
14	Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. <i>Neuro-Oncology</i> , 2019, 21, 1184-1196.	1.2	28
15	SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. <i>Journal of Neuro-Oncology</i> , 2019, 142, 423-434.	2.9	8
16	Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. <i>Scientific Reports</i> , 2019, 9, 2846.	3.3	32
17	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	30.7	932
18	Evidence for Innate and Adaptive Immune Responses in a Cohort of Intractable Pediatric Epilepsy Surgery Patients. <i>Frontiers in Immunology</i> , 2019, 10, 121.	4.8	18

#	ARTICLE	IF	CITATIONS
19	Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. <i>Clinical Cancer Research</i> , 2019, 25, 1913-1922.	7.0	57
20	Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. <i>Brain Tumor Pathology</i> , 2018, 35, 1-9.	1.7	12
21	Precision Medicine in Pediatric Neurooncology: A Review. <i>ACS Chemical Neuroscience</i> , 2018, 9, 11-28.	3.5	12
22	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. <i>Journal of Translational Medicine</i> , 2018, 16, 142.	4.4	376
23	Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 3845-3856.	7.0	35
24	Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. <i>Cancer &amp; Metabolism</i> , 2018, 6, 4.	5.0	55
25	Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now287.	1.2	128
26	Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2017, 134, 29-40.	2.9	19
27	Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10220-10225.	7.1	79
28	Implementing liquid biopsies into clinical decision making for cancer immunotherapy. <i>Oncotarget</i> , 2017, 8, 48507-48520.	1.8	63
29	PD-1 blockade enhances the vaccination-induced immune response in glioma. <i>JCI Insight</i> , 2016, 1, .	5.0	128
30	TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. <i>Cancer Immunology Research</i> , 2016, 4, 412-418.	3.4	64
31	Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 368-378.	1.2	31
32	New applications for deep sequencing of the T cell receptor repertoire in cancer patients. <i>Translational Cancer Research</i> , 2016, 5, S842-S843.	1.0	1
33	Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes. <i>Journal of Visualized Experiments</i> , 2015, , .	0.3	0
34	IMCT-10A PHASE I DOSE ESCALATION STUDY TO TEST THE SAFETY OF INTRATUMORAL ADOPTIVE IMMUNE THERAPY WITH AlloCTL IN RECURRENT GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2015, 17, v109.3-v109.	1.2	1
35	IMCT-11NEXT GENERATION T CELL RECEPTOR SEQUENCING CAN IDENTIFY, QUANTIFY, AND TRACK TUMOR-SPECIFIC T CELL POPULATIONS BEFORE AND AFTER DENDRITIC CELL VACCINATION IN GLIOBLASTOMA MULTIFORME PATIENTS. <i>Neuro-Oncology</i> , 2015, 17, v109.4-v110.	1.2	0
36	TMIC-04THERAPEUTIC ANTI-GLIOMA IMMUNITY IS DEPENDENT ON VACCINATION-INDUCED T CELL RESPONSES AND INHIBITION OF iAPC FUNCTION IN THE TUMOR MICROENVIRONMENT. <i>Neuro-Oncology</i> , 2015, 17, v214.8-v215.	1.2	0

#	ARTICLE	IF	CITATIONS
37	IMPS-19RETROVIRAL REPLICATING VECTOR-MEDIATED DELIVERY OF AN IMMUNODOMINANT NEO-ANTIGEN EPI TOPE TARGET FOR VIRO-IMMUNOTHERAPY IN EXPERIMENTAL GLIOMA. <i>Neuro-Oncology</i> , 2015, 17, v117.2-v117.	1.2	0
38	2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. <i>Cell Metabolism</i> , 2015, 22, 508-515.	16.2	190
39	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542.	10.7	582
40	pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. <i>Neuro-Oncology</i> , 2015, 17, 1514-1524.	1.2	96
41	CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy. , 2014, 2, 46.		52
42	Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in <i>IDH1</i>-Mutant Gliomas. <i>Clinical Cancer Research</i> , 2014, 20, 5808-5822.	7.0	30
43	Cytokine responsiveness of CD8+ T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. , 2014, 2, 10.		29
44	The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells. , 2014, 2, 8.		42
45	An Essential Requirement for the SCAP/SREBP Signaling Axis to Protect Cancer Cells from Lipotoxicity. <i>Cancer Research</i> , 2013, 73, 2850-2862.	0.9	148
46	Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma Patients. <i>Journal of Immunotherapy</i> , 2013, 36, 152-157.	2.4	111
47	Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. <i>Anticancer Research</i> , 2013, 33, 2047-56.	1.1	55
48	Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. <i>Neuro-Oncology</i> , 2012, 14, 1465-1472.	1.2	35
49	Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1458-1469.	6.3	56
50	Endogenous Vaults and Bioengineered Vault Nanoparticles for Treatment of Glioblastomas. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 451-458.	1.7	10
51	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. <i>Journal of Neuro-Oncology</i> , 2012, 107, 197-205.	2.9	280
52	Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients. <i>PLoS ONE</i> , 2012, 7, e32614.	2.5	83
53	Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas. <i>American Journal of Translational Research (discontinued)</i> , 2012, 4, 114-26.	0.0	8
54	An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR-Dependent Pathway. <i>Cancer Discovery</i> , 2011, 1, 442-456.	9.4	346

#	ARTICLE	IF	CITATIONS
55	Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway. <i>Journal of Translational Medicine</i> , 2011, 9, 192.	4.4	38
56	Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 1603-1615.	7.0	378
57	Enhanced Sensitivity to IL-2 Signaling Regulates the Clinical Responsiveness of IL-12-Primed CD8+ T Cells in a Melanoma Model. <i>Journal of Immunology</i> , 2011, 186, 5068-5077.	0.8	22
58	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. <i>Nature</i> , 2010, 465, 966-966.	27.8	360
59	Cellular and vaccine therapeutic approaches for gliomas. <i>Journal of Translational Medicine</i> , 2010, 8, 100.	4.4	26
60	The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12932-12937.	7.1	208
61	Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824. <i>Cancer Research</i> , 2009, 69, 8693-8699.	0.9	136
62	Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen. <i>International Immunology</i> , 2009, 21, 155-165.	4.0	43
63	EGFR Signaling Through an Akt-SREBP-1-Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy. <i>Science Signaling</i> , 2009, 2, ra82.	3.6	282
64	Immunosensitization with a Bcl-2 small molecule inhibitor. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 699-708.	4.2	19
65	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. <i>Nature</i> , 2009, 462, 739-744.	27.8	3,315
66	Harnessing T-Cell Immunity to Target Brain Tumors. , 2009, , 1165-1217.		3
67	Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1279-1289.	4.2	59
68	Cytomegalovirus Immunity after Vaccination with Autologous Glioblastoma Lysate. <i>New England Journal of Medicine</i> , 2008, 359, 539-541.	27.0	135
69	Lentiviral Vectors with CMV or MHCII Promoters Administered In Vivo: Immune Reactivity Versus Persistence of Expression. <i>Molecular Therapy</i> , 2007, 15, 1390-1399.	8.2	43
70	Central Nervous System Tumor Immunity Generated by a Recombinant <i>Listeria monocytogenes</i> Vaccine Targeting Tyrosinase Related Protein-2 and Real-Time Imaging of Intracranial Tumor Burden. <i>Neurosurgery</i> , 2006, 58, 169-178.	1.1	17
71	The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity. <i>Journal of Immunology</i> , 2006, 176, 157-164.	0.8	193
72	NK and CD4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain. <i>Journal of Immunology</i> , 2006, 177, 8448-8455.	0.8	59

#	ARTICLE	IF	CITATIONS
73	Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1481-1494.	2.8	24
74	Bioluminescent Imaging of Melanoma in Live Mice. <i>Journal of Investigative Dermatology</i> , 2005, 125, 159-165.	0.7	48
75	The TLR7 Agonist Imiquimod Enhances the Anti-Melanoma Effects of a Recombinant <i>Listeria monocytogenes</i> Vaccine. <i>Journal of Immunology</i> , 2005, 175, 1983-1990.	0.8	110
76	Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2005, 11, 5515-5525.	7.0	498
77	Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies. <i>Neurological Research</i> , 2005, 27, 692-702.	1.3	15
78	Cellular immunity and immunotherapy of brain tumors. <i>Frontiers in Bioscience - Landmark</i> , 2004, 9, 3124.	3.0	33
79	Characterization of Defective CD4 <sup>+</sup> CD8 <sup>-</sup> T Cells in Murine Tumors Generated Independent of Antigen Specificity. <i>Journal of Immunology</i> , 2004, 172, 1602-1611.	0.8	29
80	Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon- $\alpha$ and interferon- $\beta$ treatment of human glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2004, 100, 310-319.	1.6	74
81	Thymic Function and Output of Recent Thymic Emigrant T Cells During Intracranial Glioma Progression. <i>Journal of Neuro-Oncology</i> , 2003, 64, 45-54.	2.9	3
82	Thymic function and output of recent thymic emigrant T cells during intracranial glioma progression. <i>Journal of Neuro-Oncology</i> , 2003, 64, 45-54.	2.9	34
83	Contrasting effects of interleukin-2 secretion by rat glioma cells contingent upon anatomical location: accelerated tumorigenesis in the central nervous system and complete rejection in the periphery. <i>Journal of Neuroimmunology</i> , 2003, 140, 49-60.	2.3	7
84	Immunology and Immunotherapy in Neurosurgical Disease. <i>Neurosurgery</i> , 2003, 53, 144-153.	1.1	39
85	Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. <i>Cancer Research</i> , 2003, 63, 8487-91.	0.9	87
86	Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2002, 51, 179-189.	4.2	32
87	Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression. <i>Cancer Immunology, Immunotherapy</i> , 2002, 51, 190-199.	4.2	35
88	Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 285-292.	4.2	36
89	IL-6 Secretion by a Rat T9 Glioma Clone Induces a Neutrophil-Dependent Antitumor Response with Resultant Cellular, Antiglioma Immunity. <i>Journal of Immunology</i> , 2001, 166, 121-129.	0.8	42
90	Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. <i>Journal of Neurosurgery</i> , 1999, 90, 1115-1124.	1.6	224